Xinjiang Bai Hua Cun Pharma Tech Co Ltd

The company maintains a strong liquidity position, with a current ratio of 2.29, indicating that it has more than twice the current assets to cover its current liabilities. However, its liquidity risk is assessed as medium, primarily due to a negative net cash position after subtracting total debt. The price-to-book ratio of 3.57 suggests that the market values the company at a premium to its book value, while the price-to-earnings ratio of 70.41 indicates a high valuation relative to earnings. In terms of profitability, the company's return on equity (ROE) of 5.07% and return on assets (ROA) of 3.71% are below the typical thresholds for high-performing pharmaceutical firms, suggesting that it is not generating strong returns relative to its equity and asset base. The gross profit margin of 39.6% (calculated as gross profit of 153.7 million CNY on revenue of 388.3 million CNY) is in line with industry norms, but the operating margin of 11.3% (calculated as operating income of 44.0 million CNY) is relatively modest. The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification in the provided data. This lack of segment or geographic diversification increases the risk of revenue volatility due to market-specific or regulatory changes. The company's growth trajectory is not clearly defined in the provided data, as there are no forward-looking revenue projections or historical growth rates available. The absence of a clear growth narrative makes it difficult to assess the company's long-term potential. The risk assessment indicates a low dilution risk, with no significant dilution potential identified in the basic shares outstanding. However, the company's capital structure includes a small amount of long-term debt (37.5 million CNY), which could increase financial risk if not managed prudently. No recent events, such as filings or transcripts, are provided in the data to inform the company's strategic direction or operational performance.